News
PDSB
1.650
-5.71%
-0.100
PDS Biotechnology (PDSB) Receives a Buy from Alliance Global Partners
TipRanks · 2d ago
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 3d ago
Promising Advancements in Cancer Treatment Drive Buy Rating for PDS Biotechnology
TipRanks · 3d ago
Weekly Report: what happened at PDSB last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at PDSB last week (1202-1206)?
Weekly Report · 12/09 10:12
PDS BIOTECHNOLOGY REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/06 13:00
PDS Biotechnology Corporation Announces Key Opinion Leader Event on HPV16-Positive Head and Neck Cancer and Phase 3 Clinical Trial for Versamune® HPV
Barchart · 12/03 17:20
Weekly Report: what happened at PDSB last week (1125-1129)?
Weekly Report · 12/02 10:12
PDS Biotechnology Price Target Cut to $7.00/Share From $9.00 by B. Riley Securities
Dow Jones · 11/25 16:55
PDS Biotechnology Is Maintained at Buy by B. Riley Securities
Dow Jones · 11/25 16:55
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $7
Benzinga · 11/25 16:45
PDS Biotechnology price target lowered to $7 from $9 at B. Riley
TipRanks · 11/25 13:35
Strategic Changes in PDS Biotechnology’s Clinical Trial Design Position Stock as Attractive Buy Opportunity
TipRanks · 11/25 12:45
PDS BIOTECHNOLOGY CORP <PDSB.O>: B. RILEY CUTS TARGET PRICE TO $7 FROM $9
Reuters · 11/25 11:53
Weekly Report: what happened at PDSB last week (1118-1122)?
Weekly Report · 11/25 10:08
U.S. RESEARCH ROUNDUP-Domino's Pizza, Elastic NV, Snowflake
Reuters · 11/25 07:05
Weekly Report: what happened at PDSB last week (1111-1115)?
Weekly Report · 11/18 10:07
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 11/15 19:36
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 11/15 19:25
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.